Bdenza 160MG

Bdenza 160mg is a medication used to treat metastatic castration-resistant prostate cancer (mCRPC). Here are some key points about the product:

Composition:

Bdenza 160mg contains Enzalutamide, a non-steroidal antiandrogen that inhibits the androgen receptor.

Indications:

Bdenza 160mg is indicated for the treatment of:

1. Metastatic castration-resistant prostate cancer (mCRPC) in patients who have received prior chemotherapy
2. Non-metastatic castration-resistant prostate cancer (nmCRPC) in patients who have received prior chemotherapy

Mechanism of Action:

Enzalutamide works by:

1. Binding to the androgen receptor (AR) and inhibiting its activity
2. Reducing the levels of prostate-specific antigen (PSA) and slowing the growth of tumors
3. Inhibiting the growth of prostate cancer cells

Dosage and Administration:

The recommended dosage of Bdenza 160mg is:

• 160mg administered orally once daily
• Administered with or without food

Side Effects:

Common side effects of Bdenza 160mg include:

1. Fatigue
2. Nausea
3. Diarrhea
4. Decreased appetite
5. Muscle spasms
6. Hot flashes
7. Headache
8. Increased risk of fractures

Serious side effects can include:

1. Seizures
2. Increased risk of suicidal thoughts or behavior
3. Cardiac arrhythmias
4. Hypertension

Contraindications:

Bdenza 160mg is contraindicated in patients with:

1. Hypersensitivity to Enzalutamide
2. Pregnancy or breastfeeding
3. Active bleeding or a history of gastrointestinal perforation

Precautions:

1. Patients with a history of seizures should be closely monitored while receiving Bdenza 160mg.
2. Patients with a history of cardiac disease or cardiac arrhythmias should be closely monitored while receiving Bdenza 160mg.
3. Patients with a history of liver disease or liver impairment should be closely monitored while receiving Bdenza 160mg.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of fatigue, nausea, or diarrhea.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from moisture.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.